HONG KONG – Beigene Ltd. is advancing its small-molecule Bruton's tyrosine kinase (BTK) inhibitor BGB-3111 into two more global clinical trials, further exploring the efficacy of the drug candidate in treating B-cell cancers. Read More
HONG KONG – Kunshan Riboquark Pharmaceutical Technology Co. Ltd. enrolled the first patient in China for its global pivotal phase II/III study of ocular neuroprotectant candidate QPI-1007. Read More
ADELAIDE, Australia – Australian biopharmaceutical companies engaged in drug development shouldn't waste their time trying to build a flagship company in Australia, said Race Oncology Ltd. CEO Peter Molloy. Rather, they should focus on partnering with big pharma as early as possible, he told attendees of the Ausbiotech conference. Read More
Researchers at Duke-National University of Singapore (Duke-NUS) Medical School have discovered for the first time that interleukin-11 (IL-11) may be an important therapeutic target for cardiovascular (CV) fibrotic diseases, including heart and renal failure, they reported in the Nov. 13, 2017, edition of Nature. Read More
HONG KONG – A year and a half after reports of illegal vaccine sales prompted investigation by China's CFDA, a recent recall involving vaccines of substandard quality has further eroded public trust in the country toward drug safety and raised concerns of the government's loophole-ridden supervision of the space. Read More
Cynata Therapeutics Ltd., of Melbourne, Australia, said that the eighth participant has been dosed in its first trial of the mesenchymal stem cell product CYP-001 for the treatment of steroid-resistant graft-vs.-host disease, marking the halfway point for recruitment into the study. An independent data safety monitoring board review will be triggered once the patient reaches day 28 of the study. Read More
